(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of 18.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Arrowhead Pharmaceuticals's revenue in 2024 is $181,740,000.On average, 8 Wall Street analysts forecast ARWR's revenue for 2024 to be $16,761,270,114, with the lowest ARWR revenue forecast at $439,834,045, and the highest ARWR revenue forecast at $37,416,868,028. On average, 6 Wall Street analysts forecast ARWR's revenue for 2025 to be $33,751,997,312, with the lowest ARWR revenue forecast at $19,615,607,218, and the highest ARWR revenue forecast at $63,955,587,007.
In 2026, ARWR is forecast to generate $34,258,859,587 in revenue, with the lowest revenue forecast at $24,097,949,773 and the highest revenue forecast at $49,595,934,674.